Taxifolin

A flavonoid.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

2
Supporting references
0
Contradictory references
7
AI-suggested references
1
Clinical trials

General information

Taxifolin is a natural flavonoid from the polyphenols class. It can be found in various conifers, fruit, vegetables, wine, tea and cocoa. It is a potential chemoprotective agent. Taxifolin showed promising pharmacological activities in the management of inflammation, tumors, microbial infections, oxidative stress, cardiovascular, and liver disorders.

Regarding SARS-CoV-2, our AIM tool found the data that taxifolin could help against SARS-CoV-2 by inhibiting its protease. 

Taxifolin on DrugBank
(-)-Taxifolin on PubChem
(+)-Taxifolin on PubChem
Taxifolin on Wikipedia


Synonyms

(-)-Taxifolin (enantiomer); (+)-Taxifolin (enantiomer); dihydroquercetin

 

Structure image - Taxifolin

C1=CC(=C(C=C1C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O


Supporting references

Link Tested on Impact factor Notes Publication date
Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 687 Million Compounds
Preprint
in silico

(-)-Taxifolin enantiomer. Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 687 Million Compounds

Mar/03/2020
Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease
3CLpro Small molecule In silico
in silico 2.01

(+)-Taxifolin is predicted to inhibit the SARS-CoV-2 3C-like protease.

Nov/25/2020

AI-suggested references

Clinical trials

ID Title Status Phase Start date Completion date
NCT04871802 Effect of the Dietary Supplement Taxifolin Aqua on the Recovery Period After COVID-19 Pneumonia Not yet recruiting Not Applicable May/10/2021 Oct/01/2021
  • Alternative id - COVID-AQUA-1
  • Interventions - Dietary Supplement: Taxifolin Aqua
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Russian Clinical Research Center for Gerontology, Moscow, Russian Federation
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Dynamics of spirometry indices|Dynamics of ECHO CG|Dynamics of pulse wave velocity|Dynamics of augmentation index|Dynamics of biological age